EUVIMEDEUVIMED entdecken
Crossref

Atranorin Impedes Glioma Invasiveness and Progression by Inhibiting the Epithelial‐Mesenchymal Transition and Stemness in Monotherapy and in Combination Therapy With Temozolomide

Rui Zhou, Eun-Jung Ahn, Suresh R Bhosle, Ju Yeon Yu, Yi Yang, So-Yeon Park, İsa Taş, Chathurika Gamage, Sultan Pulat, Mücahit Varlı, Jae-Seoun Hur, Kyung Keun Kim und 5 weitere

Phytotherapy Research · 2026

DOI: 10.1002/ptr.70126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, 2026. Verfasst von Rui Zhou und 16 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Sunchon National University, Sunchon, Republic of Korea. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Glioma, Neoplastic Stem Cells, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lichens are commensal organisms that contain secondary metabolites such as atranorin, which have intrinsic bioactive properties, including anticancer effects. The present study aimed to investigate the therapeutic potential and molecular mechanisms of atranorin and its hydrolytic derivatives in monotherapy and in combination treatment with temozolomide in glioma. The effects of atranorin on gliomas were investigated using an MTT assay, transwell invasion assay, spheroid formation assay, clonogenic assay, reporter assay, western blotting, quantitative real‐time PCR, an orthotopic mouse glioma model with in vivo bioluminescence imaging, and immunohistochemical staining. Here, we found that atranorin inhibited glioma cell invasion and spheroid formation by downregulating epithelial‐mesenchymal transition (EMT) and cancer stemness regulators and markers. The atranorin hydrolytic derivatives atraric acid and haematommic acid inhibited glioma cell invasiveness and stemness, respectively. Also, major oncogenic signaling pathways—Wnt, AP‐1, STAT, Hedgehog, Notch, and NF‐κB—were investigated, revealing that atranorin robustly decreased the transcriptional activities of TOPFLASH, AP‐1, Gli, CBF1/Su(H)/Lag‐1, hairy/enhancer of Split, and expression of the related downstream targets such as β‐catenin, cyclin‐D1, c‐myc, c‐Jun, c‐Fos, Gli1, Gli2, Smoothened, and Notch 1 intracellular domain. Moreover, atranorin‐mediated upregulation of Dusp3 and Ptpn1 suppressed the invasiveness and stemness of gliomas by dephosphorylating STAT and NF‐κB. Importantly, atranorin exerts synergistic antiglioma effects on invasion and spheroid formation in combination treatment with temozolomide. These findings identified that atranorin could be developed as a specific therapy to target EMT and CSC pathways to suppress malignant behaviors in glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionGliomaNeoplastic Stem CellsBrain NeoplasmsTemozolomideAnimalsHumansCell Line, TumorMiceNeoplasm InvasivenessSignal TransductionMice, Nude

Stichwörter der Autor:innen

atranorinatraric acidgliomahaematommic acidprotein tyrosine phosphatasetemozolomide

Substanzen

Temozolomide

Autor:innen und Institutionen

  • College of Pharmacy, Sunchon National University, Sunchon, Republic of Korea.
  • Department of Neurosurgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun, Republic of Korea.
  • Korea Lichen Research Institute, Sunchon National University, Sunchon, Republic of Korea.
  • Department of Pharmacology, Chonnam National University Medical School, Gwangju, Republic of Korea.
  • Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun, Republic of Korea.
  • College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.

ORCID-Profile: Hangun Kim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Zhou, R., Ahn, E. J., Bhosle, S. R., Yu, J. Y., Yang, Y., Park, S. Y., Taş, İ., Gamage, C., Pulat, S., Varlı, M., Hur, J. S., Kim, K. K., Lee, K. H., Ha, H. H., Kim, S. K., Moon, K. S., & Kim, H. (2026). Atranorin Impedes Glioma Invasiveness and Progression by Inhibiting the Epithelial‐Mesenchymal Transition and Stemness in Monotherapy and in Combination Therapy With Temozolomide. Phytotherapy Research. https://doi.org/10.1002/ptr.70126

Vancouver

Zhou R, Ahn EJ, Bhosle SR, Yu JY, Yang Y, Park SY, et al. Atranorin Impedes Glioma Invasiveness and Progression by Inhibiting the Epithelial‐Mesenchymal Transition and Stemness in Monotherapy and in Combination Therapy With Temozolomide. Phytotherapy Research. 2026. doi:10.1002/ptr.70126

BibTeX
@article{Zhou2026,
  author = {Zhou, Rui and Ahn, Eun-Jung and Bhosle, Suresh R and Yu, Ju Yeon and Yang, Yi and Park, So-Yeon and Taş, İsa and Gamage, Chathurika and Pulat, Sultan and Varlı, Mücahit and Hur, Jae-Seoun and Kim, Kyung Keun and Lee, Kyung-Hwa and Ha, Hyung-Ho and Kim, Sang Kyum and Moon, Kyung-Sub and Kim, Hangun},
  title = {Atranorin Impedes Glioma Invasiveness and Progression by Inhibiting the Epithelial‐Mesenchymal Transition and Stemness in Monotherapy and in Combination Therapy With Temozolomide},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70126}
}
Kostenlos starten →